

51 51 A method of increasing the probability of a nocturnal erection in a male mammal, which comprises administering a controlled-release formulation comprising a cGMP PDE-5 inhibitor to the male mammal.

52 52 A dual release formulation for oral administration having a first portion comprising a controlled-release formulation comprising a cGMP PDE-5 inhibitor and a second portion comprising a cGMP PDE-5 inhibitor in immediate release form.

53 53. A product containing a controlled-release formulation comprising a cGMP PDE-5 inhibitor and a cGMP PDE-5 inhibitor in immediate release form, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of sexual dysfunction.

Only after the above claims have been entered, please delete claims 1-30 without waiver or prejudice.

REMARKS

The above amendments have been made in response to the Office Action.

Claims 1-4 and 18 were rejected as anticipated by US 5,656,629 to Bacon. These claims have now been canceled. It is noted that Applicants do not agree with the rejection of claims 1-4 and 18 and the rejection of these claims is being made without waiver or prejudice to Applicants' right to file a divisional application directed to this canceled subject matter.

The remaining claims (claims 5-17, 19-21, and 24-30) have been re-drafted into independent format, as appropriate, as suggested by the Examiner, including all of the limitations of intervening claims. New claims 31-53 are each a combination of the following original claims.

Claim 31 is a combination of claims 5, 2 and 1.

Claim 32 is a combination of claims 6, 2 and 1.

Claim 33 is a combination of claims 7 and 1.

Claim 34 is a combination of claims 8, 7, and 1.

Claim 35 is a combination of claims 9, 4, 2 and 1.

Claim 36 is a combination of claims 10, 4, 2 and 1.

Claim 37 is a combination of claims 11, 9, 4, 2 and 1.

Claim 38 is a combination of claims 12, 9, 4, 2, and 1.

Claim 39 is a combination of claims 13, 9, 4, 2 and 1.

Claim 40 is a combination of claims 14, 9, 4, 2 and 1.

Claim 41 is a combination of claims 15, 5, 2 and 1.

Claim 42 is a combination of claims 16, 15, 5, 2 and 1.

Claim 43 is a combination of claims 17, 5, 2 and 1.

Claim 44 is a combination of claims 19 and 1.

Claim 45 is a combination of claims 20 and 1.

Claim 46 is a combination of claims 21, 4, 2 and 1.

Claim 47 is a combination of claims 24 and 1.

Claim 48 is a combination of claims 25, 24 and 1.

Claim 49 is a combination of claims 26 and 1.

Claim 50 is a combination of claims 27, 26 and 1.

Claim 51 is a combination of claims 28 and 1.

Claim 52 is a combination of claims 29 and 1.

Claim 53 is a combination of claims 30 and 1.


Patent Application
Attorney Docket No. PC 10303AJTJ

The rejected claims have thus been canceled and the remaining claims have been re-drafted into independent format as appropriate, as suggested by the Examiner. No other issues remain for consideration in this application.

Accordingly, in view of the foregoing comments and amendments, it is respectfully submitted that this application is in condition for allowance. A Notice of allowance is respectfully requested.

Respectfully submitted,

Date: April 12, 2002


James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 519
Eastern Point Road
Groton, CT 06340
(860) 441-4903

Patent Application
Attorney Docket No. PC 10303AJTJ

VERSION MARKED UP TO SHOW CHANGES MADE

Claims 31 through 53 have been added.

After adding claims 31 through 53, claims 1 through 30 have been canceled.

C